Clinical trials to include Indian subjects, a welcome decision says CRO

By Flora Southey

- Last updated on GMT

(Image: Getty/Niyazz)
(Image: Getty/Niyazz)

Related tags Clinical trial Pharmacology

Clinical trials conducted outside of India – which test drugs for the Indian market – must include Indian subjects, according to a ruling in India last month.

The technical committee meeting​ held on September 25, 2017, was led by the director general of health services Jagdish Prasad, and decided that “any firm intending to market a new drug which is being developed outside the country, should include Indian patients.”

In the same meeting, it was determined that trials already approved in ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) countries, such as those in the US, Europe, and Japan, will be reviewed on priority by the Drugs Controller General of India (DCGI).

CRO perspective

The ruling will affect clinical research organisations’ (CROs) recruitment procedures for drug trials intended for the Indian market.

According to CRO George Clinical – which conducts clinical trials globally, including India – the decision will boost the effectiveness of medicines marketed in the country.

“This is an important move in determining the efficacy of drugs marketed in India,” ​said the firm’s managing director Vanaja Krishnan.

“After a series of events that impacted negatively on the sector in India in the early part of this decade, the decisions reached in the technical committee meeting reflect India’s harmonisation with international trial requirements,” ​she said.

Krishnan said the decision will encourage drug firms to include India​ in global trials. 

“It shows a reinvigoration of confidence in the clinical trials environment in India, and will encourage the inclusion of India in global trial programmes,” ​she explained.

“Global sponsors will again consider India as an important part of their research and development programme.”

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars